Document Detail


Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.
MedLine Citation:
PMID:  22913659     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Dexrazoxane (DEX), an inhibitor of topoisomerase II and intracellular iron chelator, is believed to reduce the formation of reactive oxygen species (ROS) and protects the heart from the toxicity of anthracycline antineoplastics. As ROS also play a role in the pathogenesis of cardiac ischaemia/reperfusion (I/R) injury, the aim was to find out whether DEX can improve cardiac ischaemic tolerance. DEX in a dose of 50, 150, or 450 mg·(kg body mass)(-1) was administered intravenously to rats 60 min before ischaemia. Myocardial infarct size and ventricular arrhythmias were assessed in anaesthetized open-chest animals subjected to 20 min coronary artery occlusion and 3 h reperfusion. Arrhythmias induced by I/R were also assessed in isolated perfused hearts. Only the highest dose of DEX significantly reduced infarct size from 53.9% ± 4.7% of the area at risk in controls to 37.5% ± 4.3% without affecting the myocardial markers of oxidative stress. On the other hand, the significant protective effect against reperfusion arrhythmias occurred only in perfused hearts with the dose of DEX of 150 mg·kg(-1), which also tended to limit the incidence of ischaemic arrhythmias. It is concluded that DEX in a narrow dose range can suppress arrhythmias in isolated hearts subjected to I/R, while a higher dose is needed to limit myocardial infarct size in open-chest rats.
Authors:
Jan Neckář; Adéla Boudíková; Petra Mandíková; Martin Stěrba; Olga Popelová; Ivan Mikšík; Ludmila Dabrowská; Jaroslav Mráz; Vladimír Geršl; František Kolář
Related Documents :
2481159 - Circadian variation of cardiovascular disease and sympathetic activity.
2211269 - Preseason cardiovascular examination: a review.
18926329 - Long-term outcome and risk stratification in dilated cardiolaminopathies.
6958189 - Bio-behavioural perspectives on coronary heart disease, hypertension and sudden cardiac...
17171889 - Reduction in mortality from cardiac causes in goldman class iv patients.
1042009 - The role of ambulatory monitoring in postinfarction patients.
18086929 - Initial aspirin dose and outcome among st-elevation myocardial infarction patients trea...
16404229 - Cerebral perfusion heterogeneity and complexity in patients with acute subarachnoid hae...
1677109 - Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-22
Journal Detail:
Title:  Canadian journal of physiology and pharmacology     Volume:  -     ISSN:  1205-7541     ISO Abbreviation:  Can. J. Physiol. Pharmacol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372712     Medline TA:  Can J Physiol Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
a Institute of Physiology, Academy of Sciences of the Czech Republic, Vídeňská 1083, 142 20 Prague 4, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medical specialty considerations by medical students early in their clinical experience.
Next Document:  Outbreak of Mycobacterium chelonae infection associated with tattoo ink.